
Rare-disease drug firm BioMarin has finalised its purchase of muscular disease specialist Prosensa in a deal worth over $840 million. …

Dutch biopharma firm Prosensa has appointed Willem W. van Weperen as chief commercial officer and Dr Annalisa Jenkins to its …

An experimental treatment by GSK and Prosensa for a rare type of muscle-degenerating disease has failed to meet its primary …
GSK has extended its research alliance with biotech company Prosensa in the field of muscular dystrophy. Netherlands-based Prosensa focuses on …

